Valuation: Patrys Limited

Market Cap 23.33M 16.61M 14.22M 13.27M 12.18M 22.88M 1.59B 157M 61.37M 797M 62.37M 61.02M 2.64B P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 22.59M 16.08M 13.77M 12.85M 11.79M 22.15M 1.54B 152M 59.42M 771M 60.39M 59.08M 2.55B EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 week+6.45%
1 month-8.33%
3 months-8.33%
6 months-2.94%
Current year+17.86%
1 week 0.03
Extreme 0.032
0.03
1 month 0.03
Extreme 0.031
0.04
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.014999
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.56
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 15/02/2026
Chief Operating Officer - 31/05/2012
Corporate Secretary - 09/11/2025
Director TitleAgeSince
Director/Board Member - 16/06/2025
Chairman 64 -
Director/Board Member - 09/11/2025
Date Insider Type Main position Quantity % Market Cap.
11/08/23 Expiration

Chief Executive Officer

396,132 0.0193%
11/08/23 Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21 Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+6.45%+120.01%-69.44% 15.19M
+2.38%+3.43%+82.88%+115.89% 72.21B
+0.87%+17.34%+57.17%+97.28% 63.98B
-4.27%-0.99%-3.38%+475.61% 28.53B
-1.97%+20.38%-0.37%+0.48% 28.42B
+1.73%+11.87%+61.24%+26.88% 25.07B
-0.51%+5.73%+38.71%-12.79% 20.04B
-1.79%-4.84%+239.54%+414.48% 18.19B
+1.41%+4.23%+19.55%+538.24% 15.96B
-1.29%+6.09%+41.81%+154.45% 13.48B
Average -0.31%+4.64%+65.72%+174.11% 28.59B
Weighted average by Cap. +0.21%+7.70%+59.75%+163.72%

Financials

2024 2025
Net sales 1.39M 993K 850K 793K 728K 1.37M 94.98M 9.41M 3.67M 47.6M 3.73M 3.65M 158M 829K 590K 505K 471K 432K 813K 56.45M 5.59M 2.18M 28.29M 2.22M 2.17M 93.65M
Net income -3.54M -2.52M -2.16M -2.01M -1.85M -3.47M -241M -23.88M -9.31M -121M -9.46M -9.26M -400M -3.01M -2.15M -1.84M -1.71M -1.57M -2.96M -205M -20.33M -7.93M -103M -8.06M -7.88M -341M
Net Debt -2.24M -1.6M -1.37M -1.27M -1.17M -2.2M -153M -15.12M -5.89M -76.5M -5.99M -5.86M -253M -742K -529K -453K -422K -387K -728K -50.58M -5.01M -1.95M -25.35M -1.98M -1.94M -83.92M
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
21/08/26 A$0.0330 0.00% 250
20/08/26 A$0.0330 +3.13% 238,219
19/08/26 A$0.0320 0.00% 3,374
18/08/26 A$0.0320 0.00% 1
17/08/26 A$0.0320 +3.23% 59,046